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Oxaliplatin is a third-generation platinum compound with activity
in advanced colorectal cancer. It is available in several European
countries, but remains investigational in North America. Its safety
profile compares favourably with the other platinum-based agents,
cisplatin and carboplatin, and consists mostly of peripheral
neuropathy and mild thrombocytopenia. However, there has been
one previous report in the literature of fatal haemolytic anaemia
caused by oxaliplatin (Desrame et al, 1999). Here we report
immune-mediated thrombocytopenia and concurrent haemolytic
anaemia (Evan’s syndrome) that developed during oxaliplatin
infusion. 
In November of 1999, a 56-year-old man with a 2-year history
of colon cancer metastatic to liver and lung, who had progressed
on first-line 5-FU and leucovorin as well as second-line irinotecan,
was enrolled on a Phase II study at the Dana-Farber Cancer
Institute. Treatment consisted of oxaliplatin 85 mg/m2 by bolus
infusion over 2 hours, followed by 500 mg/m2 of leucovorin also
infused over 2 hours, 5-FU 400 mg/m2 by rapid venous infusion,
and then 5-FU 2400 mg/m2 by continuous infusion with a portable
pump over 46 hours. Treatment was repeated every 2 weeks. The
patient had stable disease on this regimen between November
1999 and July 2000. 
In July, the patient came for a routine treatment with a platelet
count of 99 000 ml–1 immediately prior to infusion. During the
leucovorin infusion, approximately 5 hours after the baseline
bloodwork was drawn and the oxaliplatin infusion initiated, he
began feeling unwell and his gums began to bleed. He subse-
quently developed purpura on his oral mucosa and eyelids, haema-
turia and haematochezia. A repeat platelet count was 6000 ml–1.He
remained haemodynamically stable throughout, and initial haemo-
globin and INR were normal. He was admitted to hospital for
platelet transfusion and supportive care, but quickly also devel-
oped anaemia with a drop in his haemoglobin from 108 to 78 g l–1.
Peripheral smear confirmed the decreased platelets, with a left
shift in red cell morphology. There was anisocytosis and polychro-
masia, with a high RDW of 17.3 and increased reticulocytes at
4.7%. Bilirubin rose to 4.4 mg dl–1, with only 1.4 mg dl–1 being
direct, and the LDH increased to 2148 U l–1. Laboratory testing
indicated a warm antibody, with a positive direct Coomb’s test
with polyspecific IgG. There was no anti-C3 antibody, and the
eluate reacted with all cells. His INR also rose transiently to 2.4.
Clotting factor levels and fibrinogen were normal, although Fibrin
Split Products were elevated at 8 mg ml–1.Screening for heparin-
induced thrombocytopenia and thrombosis (HITT) was negative.
The patient was treated with prednisone 75 mg orally per day,
with stabilization of his blood indices over the course of 3 days
after receiving a total of 4 units of single donor platelets, 3 units of
packed red blood cells, and 4 units of fresh frozen plasma. He
made a complete clinical recovery, with a platelet count of
122 000 ml21 and a hemoglobin of 109 g l21 2 weeks later while
tapering off the steroids. In the month since this episode he has had
continued disease stability, but he has not been re-challenged with
oxaliplatin. 
Haemolytic anaemia has previously been reported with cisplatin
(Levi et al, 1981) and carboplatin (Marani et al, 1996), as well as
oxaliplatin. In contrast to the previous case report of oxaliplatin-
mediated haemolytic anaemia, our patient recovered with
supportive treatment. The lack of anti-C3 and the fact that the
eluate reacted with all cells is less consistent with a drug-induced
haemolysis, but the timing and rapidity with which the thrombo-
cytopenia developed is highly suggestive of an immune-mediated
cause. To our knowledge there have been no previous reports of
immune-mediated platelet destruction due to oxaliplatin associ-
ated with, and preceding, haemolytic anaemia. 
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